<mediawiki xmlns="http://www.mediawiki.org/xml/export-0.10/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.mediawiki.org/xml/export-0.10/ http://www.mediawiki.org/xml/export-0.10.xsd" version="0.10" xml:lang="en">
  <siteinfo>
    <sitename>Wikipedia</sitename>
    <dbname>enwiki</dbname>
    <base>https://en.wikipedia.org/wiki/Main_Page</base>
    <generator>MediaWiki 1.28.0-wmf.22</generator>
    <case>first-letter</case>
    <namespaces>
      <namespace key="-2" case="first-letter">Media</namespace>
      <namespace key="-1" case="first-letter">Special</namespace>
      <namespace key="0" case="first-letter" />
      <namespace key="1" case="first-letter">Talk</namespace>
      <namespace key="2" case="first-letter">User</namespace>
      <namespace key="3" case="first-letter">User talk</namespace>
      <namespace key="4" case="first-letter">Wikipedia</namespace>
      <namespace key="5" case="first-letter">Wikipedia talk</namespace>
      <namespace key="6" case="first-letter">File</namespace>
      <namespace key="7" case="first-letter">File talk</namespace>
      <namespace key="8" case="first-letter">MediaWiki</namespace>
      <namespace key="9" case="first-letter">MediaWiki talk</namespace>
      <namespace key="10" case="first-letter">Template</namespace>
      <namespace key="11" case="first-letter">Template talk</namespace>
      <namespace key="12" case="first-letter">Help</namespace>
      <namespace key="13" case="first-letter">Help talk</namespace>
      <namespace key="14" case="first-letter">Category</namespace>
      <namespace key="15" case="first-letter">Category talk</namespace>
      <namespace key="100" case="first-letter">Portal</namespace>
      <namespace key="101" case="first-letter">Portal talk</namespace>
      <namespace key="108" case="first-letter">Book</namespace>
      <namespace key="109" case="first-letter">Book talk</namespace>
      <namespace key="118" case="first-letter">Draft</namespace>
      <namespace key="119" case="first-letter">Draft talk</namespace>
      <namespace key="446" case="first-letter">Education Program</namespace>
      <namespace key="447" case="first-letter">Education Program talk</namespace>
      <namespace key="710" case="first-letter">TimedText</namespace>
      <namespace key="711" case="first-letter">TimedText talk</namespace>
      <namespace key="828" case="first-letter">Module</namespace>
      <namespace key="829" case="first-letter">Module talk</namespace>
      <namespace key="2300" case="first-letter">Gadget</namespace>
      <namespace key="2301" case="first-letter">Gadget talk</namespace>
      <namespace key="2302" case="case-sensitive">Gadget definition</namespace>
      <namespace key="2303" case="case-sensitive">Gadget definition talk</namespace>
      <namespace key="2600" case="first-letter">Topic</namespace>
    </namespaces>
  </siteinfo>
  <page>
    <title>Valproate</title>
    <ns>0</ns>
    <id>57761</id>
    <revision>
      <id>746117181</id>
      <parentid>745445462</parentid>
      <timestamp>2016-10-25T10:21:26Z</timestamp>
      <contributor>
        <ip>182.65.65.11</ip>
      </contributor>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="56943">{{drugbox
| Watchedfields = changed
| verifiedrevid = 477003327
| IUPAC_name = 2-propylpentanoic acid
| image = Valproic_acid.svg
| image2 = Valproic acid 3d structure.png
&lt;!--Clinical data--&gt;
| tradename = Convulex, Depakote, Epilim, Stavzor, Vilapro
| Drugs.com = {{drugs.com|monograph|valproic_acid}}
| MedlinePlus = a682412p
| licence_US = Valproic+acid
| pregnancy_AU = D
| pregnancy_US = X
| pregnancy_US_comment = - for control of conditions other than severe epilepsy not amenable to other drugs
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[Oral administration|By mouth]], [[intravenous therapy|intravenous]]
&lt;!--Pharmacokinetic data--&gt;
| bioavailability = Rapid absorption
| protein_bound = 80–90%&lt;ref name = MSR&gt;{{cite web|title=Depakene, Stavzor (valproic acid) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=13 February 2014|url=http://reference.medscape.com/drug/depakene-stavzor-valproic-acid-343024#showall}}&lt;/ref&gt;
| metabolism = [[Liver|Hepatic]]—[[glucuronidation|glucuronide conjugation]] 30–50%, [[mitochondrial β-oxidation]] over 40%
| elimination_half-life = 9–16 hours&lt;ref name = MSR/&gt; 
| excretion = Urine (30-50%)&lt;ref name = MSR/&gt;
&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 99-66-1
| ATC_prefix = N03
| ATC_suffix = AG01
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 39867
| PubChem = 3121
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00313
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3009
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 614OI1Z5WI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00399
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 109
| NIAID_ChemDB = 057177
| synonyms = 2-Propylvaleric acid
&lt;!--Chemical data--&gt;
| C=8 | H=16 | O=2
| molecular_weight = 144.211 g/mol
| smiles = O=C(O)C(CCC)CCC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NIJJYAXOARWZEE-UHFFFAOYSA-N
}}
&lt;!-- Definition and medical uses --&gt;
'''Valproate''' ('''VPA'''), and its '''valproic acid''', '''sodium valproate''', and '''divalproex sodium''' forms, are medications primarily used to treat [[epilepsy]] and [[bipolar disorder]] and to prevent [[migraine headache]]s.&lt;ref name=AHFS2015&gt;{{cite web|title=Valproic Acid|url=http://www.drugs.com/monograph/valproic-acid.html|publisher=The American Society of Health-System Pharmacists|accessdate=Oct 23, 2015}}&lt;/ref&gt; It is useful for the prevention of seizures in those with [[absence seizure]]s, [[partial seizure]]s, and [[generalized seizure]]s.&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; It can be given [[intravenous]]ly or by mouth.&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; Long acting formulations exist.&lt;ref name=AHFS2015/&gt;

&lt;!-- Side effects and mechanism --&gt;
Common side effects include nausea, vomiting, sleepiness, and a dry mouth.&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; Serious side effects can include liver problems and regular monitoring of [[liver function test]]s is therefore recommended.&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; Other serious risks include [[pancreatitis]] and an increased [[suicide]] risk.&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; It is known to cause serious abnormalities in the baby if taken during [[pregnancy]].&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; Because of this it is not typically recommended in women of childbearing age who have migraines.&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; It is unclear how valproate works.&lt;ref name=AHFS2015/&gt;

&lt;!-- History, society, and culture --&gt;
Valproate was first made in 1881 and came into medical use in 1962.&lt;ref&gt;{{cite book|last1=Scott|first1=D.F.|title=The history of epileptic therapy : an account of how medication was developed|date=1993|publisher=Parthenon Publ. Group|location=Carnforth u.a.|isbn=9781850703914|page=131|edition=1. publ.|url=https://books.google.ca/books?id=8DlOOps7D4oC&amp;pg=PA131}}&lt;/ref&gt; It is on the [[World Health Organization's List of Essential Medicines]], the most important medications needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of Essential Medicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|format=PDF|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt; It is available as a [[generic medication]].&lt;ref name=AHFS2015/&gt; The wholesale cost in the [[developing world]] is between 0.14 and 0.52 [[United States dollar|USD]] per day.&lt;ref&gt;{{cite web|title=Sodium Valproate|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&amp;code=NAV500T&amp;s_year=2014&amp;year=2014&amp;str=500%20mg&amp;desc=Sodium%20Valproate&amp;pack=new&amp;frm=TAB-CAP&amp;rte=PO&amp;class_code2=24%2E2%2E2%2E&amp;supplement=&amp;class_name=%2824%2E2%2E2%2E%29Medicines%20used%20in%20bipolar%20disorders%3Cbr%3E|website=International Drug Price Indicator Guide}}&lt;/ref&gt; In the United States it costs about 0.90 USD per day.&lt;!-- &lt;ref name=AHFS2015/&gt; --&gt; It is marketed under the brand name '''Depakote''' among others.&lt;ref name=AHFS2015/&gt;

{{TOC limit|3}}

==Terminology==
Valproic acid (VPA) is an [[organic compound|organic]] weak [[acid]]. The [[conjugate acid|conjugate base]] is valproate. The sodium [[salt (chemistry)|salt]] of the acid is sodium valproate and a [[coordination complex]] of the two is known as divalproex sodium.

==Medical uses==
It is used primarily to treat [[epilepsy]] and [[bipolar disorder]]. It is also used to prevent [[migraine headache]]s.&lt;ref name = AMH/&gt;

===Epilepsy===
Valproate has a broad spectrum of [[anticonvulsant]] activity, although it is primarily used as a first-line treatment for [[tonic-clonic seizures]], [[absence seizures]] and [[myoclonic seizures]] and as a second-line treatment for [[partial seizures]] and [[infantile spasms]].&lt;ref name = AMH/&gt;&lt;ref&gt;{{cite journal | vauthors = Löscher W | title = Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy | journal = CNS Drugs | volume = 16 | issue = 10 | pages = 669–694 | year = 2002 | pmid = 12269861 | doi = 10.2165/00023210-200216100-00003 }}&lt;/ref&gt; It has also been successfully given [[Intravenous therapy|intravenously]] to treat [[status epilepticus]].&lt;ref&gt;{{cite journal | vauthors = Olsen KB, Taubøll E, Gjerstad L | title = Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults | journal = Acta Neurol. Scand., Suppl.c | volume = 187 | pages = 51–4 | year = 2007 | pmid = 17419829 | doi = 10.1111/j.1600-0404.2007.00847.x }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Kwan SY | title = The role of intravenous valproate in convulsive status epilepticus in the future | journal = Acta Neurol Taiwan | volume = 19 | issue = 2 | pages = 78–81 | year = 2010 | pmid = 20830628 | url = http://www.ant.org.tw/Mag_Files/19-2/N201072314227_192edi.pdf | format = PDF }}&lt;/ref&gt;

===Psychiatric disorders===
Valproate products are also used to treat manic or mixed episodes of [[bipolar disorder]].&lt;ref name=&quot;:1&quot;&gt;{{cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm192645.htm |title=Valproate Information |publisher=Fda.gov |date= |accessdate=2015-04-24}}&lt;/ref&gt;

Off-label uses include [[impulse control disorders]], suggested by recent evidence of efficacy in controlling this adverse effect of [[Parkinson's disease]] medical therapy.&lt;ref name=Hicks/&gt;

=== Migraines ===
Valproate is also used to prevent [[Migraine|migraine headaches]]. Because this medication can be potentially harmful to the fetus, valproate should be considered for women of childbearing potential only after the risks have been discussed.&lt;ref name=&quot;:0&quot; /&gt;

===Other===
The medication has been tested in the treatment of [[AIDS]] and [[cancer]], owing to its [[Histone deacetylase inhibitor|histone deacetylase-inhibiting effects]].&lt;ref&gt;{{cite journal | vauthors = Činčárová L, Zdráhal Z, Fajkus J | title = New perspectives of valproic acid in clinical practice | journal = Expert Opin Investig Drugs | volume = 22 | issue = 12 | pages = 1535–1547 | year = 2013 | pmid = 24160174 | doi = 10.1517/13543784.2013.853037 }}&lt;/ref&gt;

==Adverse effects==
{{See also|List of adverse effects of valproic acid|List of adverse effects of valproate semisodium}}
{{colbegin|2}}
Most common adverse effects include:&lt;ref name=&quot;:0&quot;&gt;{{cite web|title=DEPAKOTE- divalproex sodium tablet, delayed release|url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08a65cf4-7749-4ceb-6895-8f4805e2b01f|accessdate=10 November 2015}}&lt;/ref&gt;
* Nausea (22%)
* [[Somnolence|Drowsiness]] (19%)
* Dizziness (12%)
* Vomiting (12%)
* [[Weakness]] (10%)

Serious adverse effects include:&lt;ref name=&quot;:0&quot; /&gt;
* Bleeding
* [[Thrombocytopenia|Low blood platelets]]
* [[Encephalopathy]]
* Suicidal behavior and thoughts
* [[Hypothermia|Low body temperature]]
{{colend}}

Valproic acid has a [[black box warning]] for [[hepatotoxicity]], [[pancreatitis]], and fetal abnormalities.&lt;ref name=&quot;:0&quot; /&gt;

===Other possible side effects===
There is evidence that valproic acid may cause premature growth plate [[ossification]] in children and adolescents, resulting in decreased height.&lt;ref&gt;[http://www.ncbi.nlm.nih.gov/pubmed/15032379 Effects of valproic acid on longitudinal bone... [J Child Neurol. 2004&amp;#93; - PubMed - NCBI&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;&lt;ref&gt;[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2013195/ Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;&lt;ref&gt;[http://onlinelibrary.wiley.com/doi/10.1046/j.1528-1157.2001.416800.x/pdf Long-Term Valproate and Lamotrigine Treatment May Be a Marker for Reduced Growth and Bone Mass in Children with Epilepsy - Guo - 2002 - Epilepsia - Wiley Online Library&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;&lt;ref&gt;[http://www.ncbi.nlm.nih.gov/pubmed/11580761 Long-term valproate and lamotrigine treatment may ... [Epilepsia. 2001&amp;#93; - PubMed - NCBI&lt;!-- Bot generated title --&gt;]&lt;/ref&gt; Valproic acid can also cause [[mydriasis]], a dilation of the pupils.&lt;ref&gt;{{cite web|url=http://www.ehealthme.com/ds/depakote/mydriasis |title=Could Depakote cause Mydriasis |publisher=eHealthMe.com |date=2014-11-18 |accessdate=2015-04-24}}&lt;/ref&gt; There is evidence that shows valproic acid may increase the chance of [[polycystic ovary syndrome]] (PCOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PCOS is higher in women with epilepsy compared to those with bipolar disorder.&lt;ref&gt;{{Cite journal|url = http://www.tandfonline.com/doi/full/10.1080/09513590802288259|title = Polycystic ovary syndrome in women using valproate: a review.|last = Bilo|first = Leonilda|date = October 2008|journal = Gynecological Endocrinology|doi = 10.1080/09513590802288259|pmid = 19012099|access-date = |last2 = Meo|first2 = Roberta}}&lt;/ref&gt;

===Pregnancy===
Valproate causes birth defects; exposure during [[pregnancy]] is associated with about three times as many major abnormalities as usual, mainly [[spina bifida]] with the risks being related to the strength of medication used and use of more than one drug.&lt;ref name=&quot;pmid6402356&quot;&gt;{{cite journal  |vauthors=Koch S, Göpfert-Geyer I, Jäger-Roman E, etal |title=[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development] |language=German |journal=Dtsch. Med. Wochenschr. |volume=108 |issue=7 |pages=250–7 |date=February 1983 |pmid=6402356 |doi= 10.1055/s-2008-1069536|url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid10882750&quot;&gt;{{cite journal  |vauthors=Moore SJ, Turnpenny P, Quinn A, etal |title=A clinical study of 57 children with fetal anticonvulsant syndromes |journal=J. Med. Genet. |volume=37 |issue=7 |pages=489–97 |date=July 2000 |pmid=10882750 |doi= 10.1136/jmg.37.7.489|url=http://jmg.bmj.com/cgi/pmidlookup?view=long&amp;pmid=10882750 |pmc=1734633}}&lt;/ref&gt; More rarely, with several other defects, possibly including a &quot;valproate syndrome&quot;.&lt;ref&gt;{{cite journal | vauthors = Ornoy A | title = Valproic acid in pregnancy: how much are we endangering the embryo and fetus? | journal = Reprod. Toxicol. | volume = 28 | issue = 1 | pages = 1–10 | year = 2009 | pmid = 19490988 | pmc =  | doi = 10.1016/j.reprotox.2009.02.014 }}&lt;/ref&gt; Characteristics of this valproate syndrome include facial features that tend to evolve with age, including a [[trigonocephaly|triangle-shaped forehead]], tall forehead with bifrontal narrowing, [[epicanthic fold]]s, medial deficiency of eyebrows, flat nasal bridge, broad [[nasal root]], anteverted nares, shallow [[philtrum]], long upper lip and thin [[vermillion border]]s, thick lower lip and small downturned mouth.&lt;ref&gt;{{cite journal | vauthors = Kulkarni ML, Zaheeruddin M, Shenoy N, Vani HN | title = Fetal valproate syndrome | journal = Indian J Pediatr | volume = 73 | issue = 10 | pages = 937–939 | year = 2006 | pmid = 17090909 | doi = 10.1007/bf02859291 }}&lt;/ref&gt; While [[developmental delay]] is usually associated with altered physical characteristics ([[dysmorphic feature]]s), this is not always the case.&lt;ref name=&quot;pmid15491979&quot;&gt;{{cite journal  |vauthors=Adab N, Kini U, Vinten J, etal |title=The longer term outcome of children born to mothers with epilepsy |journal=J. Neurol. Neurosurg. Psychiatr. |volume=75 |issue=11 |pages=1575–83 |date=November 2004 |pmid=15491979 |doi=10.1136/jnnp.2003.029132 |url=http://jnnp.bmj.com/cgi/content/full/75/11/1575 |quote=This argues that the fetal valproate syndrome constitutes a real clinical entity that includes developmental delay and cognitive impairments, but that some children might exhibit some developmental delay without marked dysmorphism. |pmc=1738809}}&lt;/ref&gt;

Children of mothers taking valproate during pregnancy are at risk for lower [[IQ]]s.&lt;ref&gt;{{cite journal | vauthors = Umur AS, Selcuki M, Bursali A, Umur N, Kara B, Vatansever HS, Duransoy YK | title = Simultaneous folate intake may prevent adverse effect of valproic acid on neurulating nervous system | journal = Childs Nerv Syst | volume = 28 | issue = 5 | pages = 729–737 | year = 2012 | pmid = 22246336 | pmc =  | doi = 10.1007/s00381-011-1673-9 }}&lt;/ref&gt;&lt;ref&gt;{{cite web | url = http://www.medscape.com/viewarticle/549073 | title = NEAD: In Utero Exposure To Valproate Linked to Poor Cognitive Outcomes in Kids | last = Cassels | first = Caroline | date = December 8, 2006 | publisher = Medscape | accessdate = 2007-05-23}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC | title = In utero antiepileptic drug exposure: fetal death and malformations | journal = Neurology | volume = 67 | issue = 3 | pages = 407–412 | year = 2006 | pmid = 16894099 | pmc = 1986655 | doi = 10.1212/01.wnl.0000227919.81208.b2 }}&lt;/ref&gt; Maternal valproate use during pregnancy has been associated with a significantly higher probability of [[autism spectrum|autism]] in the offspring.&lt;ref&gt;{{cite journal | vauthors = Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M | title = Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism | journal = JAMA | volume = 309 | issue = 16 | pages = 1696–1703 | year = 2013 | pmid = 23613074 | pmc =  | doi = 10.1001/jama.2013.2270 }}&lt;/ref&gt; A 2005 study found rates of autism among children exposed to sodium valproate before birth in the cohort studied were 8.9%.&lt;ref name=&quot;pmid16108456&quot;&gt;{{cite journal  |vauthors=Rasalam AD, Hailey H, Williams JH, etal |title=Characteristics of fetal anticonvulsant syndrome associated autistic disorder |journal=Dev Med Child Neurol |volume=47 |issue=8 |pages=551–5 |date=August 2005 |pmid=16108456 |doi= 10.1017/S0012162205001076|url=http://www.blackwell-synergy.com/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0012-1622&amp;date=2005&amp;volume=47&amp;issue=8&amp;spage=551}}&lt;/ref&gt; The normal incidence for autism in the general population is estimated at less than one percent.&lt;ref&gt;[http://www.autism-society.org/site/PageServer?pagename=about_home Autism Society of America: About Autism&lt;!-- Bot generated title --&gt;]&lt;/ref&gt; A 2009 study found that the 3-year-old children of pregnant women taking valproate had an IQ nine points lower than that of a well-matched control group. However, further research in older children and adults is needed.&lt;ref&gt;[http://www.nytimes.com/2009/04/16/health/research/16child.html I.Q. Harmed by Epilepsy Drug in Utero] By RONI CARYN RABIN, ''New York Times'', April 15, 2009&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW | title = Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs | journal = N. Engl. J. Med. | volume = 360 | issue = 16 | pages = 1597–1605 | year = 2009 | pmid = 19369666 | pmc = 2737185 | doi = 10.1056/NEJMoa0803531 }}&lt;/ref&gt;&lt;ref&gt;[http://www.drugs.com/fda/valproate-products-safety-communication-risk-impaired-cognitive-development-children-exposed-utero-12994.html Valproate Products: Drug Safety Communication - Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy)]. FDA. June 2011&lt;/ref&gt;

Sodium valproate has been associated with the rare condition [[Paroxysmal tonic upgaze|paroxysmal tonic]] upgaze of childhood, also known as Ouvrier–Billson syndrome, from childhood or fetal exposure. This condition resolved after discontinuing valproate therapy.&lt;ref&gt;{{Cite journal|url = http://www.ncbi.nlm.nih.gov/pubmed/17884759|title = Paroxysmal tonic upgaze of childhood with co-existent absence epilepsy.|last = Luat|first = AF|date = 20 September 2007|journal = Epileptic Disorders|doi = |pmid = |access-date = 11 November 2015}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal|url = http://www.ncbi.nlm.nih.gov/pubmed/3209843|title = Benign paroxysmal tonic upgaze of childhood.|last = Ouvrier|first = RA|date = July 1988|journal = Journal of Child Neurology|doi = |pmid = |access-date = }}&lt;/ref&gt;

Women who intend to become pregnant should switch to a different medication if possible, or decrease their dose of valproate.&lt;ref&gt;[http://www.lawyersandsettlements.com/lawsuit/valproate-not-to-be-used-migraine-during-pregnancy.html#.UZPulit35cI Valproate Not To Be Used for Migraine During Pregnancy, FDA Warns&lt;!-- Bot generated title --&gt;]&lt;/ref&gt; Women who become pregnant while taking valproate should be warned that it causes birth defects and cognitive impairment in the newborn, especially at high doses (although valproate is sometimes the only drug that can control seizures, and seizures in pregnancy could have even worse consequences.) Studies have shown that taking [[folic acid]] can reduce the risk of congenital [[neural tube]] defects.&lt;ref name=&quot;:0&quot; /&gt;

===Elderly===

Valproate in elderly people with dementia caused increased sleepiness. More people stopped the medication for this reason. Additional side effects of weight loss and decreased food intake was also associated in one half of people who become sleepy.&lt;ref name=&quot;:0&quot; /&gt;

===Contraindications===

Contraindications include:&lt;ref name = TGA&gt;{{cite web|title=Valpro sodium valproate|work=TGA eBusiness Services|publisher=Alphapharm Pty Limited|date=16 December 2013|accessdate=14 February 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2010-PI-04603-3|format=PDF}}&lt;/ref&gt;
* Pregnancy
* Pre-existing acute or chronic liver dysfunction or family history of severe [[hepatitis|liver inflammation]] (hepatitis), particularly medicine related. 
* Known [[hypersensitivity]] to valproate or any of the ingredients used in the preparation{{citation needed|date=October 2016}}
* Urea cycle disorders
* Hepatic [[porphyria]]
*Hepatotoxicity&lt;ref name = TGA/&gt;
*[[Mitochondrial disease]]&lt;ref name = TGA/&gt;
*[[Pancreatitis]]&lt;ref name = TGA/&gt;
* [[Porphyria]]&lt;ref name = EMC&gt;{{cite web|title=Depakote 250mg Tablets - Summary of Product Characteristics|work=electronic Medicines Compendium|publisher=Sanofi|date=28 November 2013|accessdate=18 January 2014|url=http://www.medicines.org.uk/emc/medicine/25929/SPC/Depakote+250mg+Tablets/}}&lt;/ref&gt;

=== Interactions ===

Valproate inhibits [[CYP2C9]], [[glucuronyl transferase]], and [[epoxide hydrolase]] and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves.&lt;ref name = TGA/&gt; It may also potentiate the CNS depressant effects of alcohol.&lt;ref name = TGA/&gt; It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including [[carbamazepine]], [[lamotrigine]], [[phenytoin]] and [[Phenobarbital|phenobarbitone]]) and itself.&lt;ref name = TGA/&gt; It may also interact with:&lt;ref name=&quot;:0&quot; /&gt;&lt;ref name = TGA/&gt;&lt;ref&gt;{{Cite journal|url = |title = Serum Valproate Levels with Oral Contraceptive Use|last = Herzog|first = Andrew|date = June 9, 2005|journal = Epilepsia|doi = 10.1111/j.1528-1167.2005.00605.x|pmid = |last2 = Farina|first2 = Erin}}&lt;/ref&gt;

* [[Aspirin]]: may increase valproate concentrations. May also interfere with valproate's metabolism.
* [[Benzodiazepine]]s: may cause CNS depression and there are possible pharmacokinetic interactions.
* [[Carbapenem]] antibiotics: reduces valproate levels, potentially leading to seizures.
* [[Cimetidine]]: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
* [[Erythromycin]]: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
* [[Ethosuximide]]: may increase ethosuximide concentrations and lead to toxicity.
* [[Felbamate]]: may increase plasma concentrations of valproate.
* [[Mefloquine]]: may increase valproate metabolism combined with the direct epileptogenic effects of mefloquine. 
* [[Oral contraceptive pill|Oral contraceptives]]: may reduce plasma concentrations of valproate. 
* [[Primidone]]: may decrease pyrimidone clearance leading to toxicity.
* [[Rifampicin|Rifampin]]: increases the clearance of valproate, leading to decreased valproate concentrations
* [[Warfarin]]: may increase warfarin concentration and prolong bleeding time.
* [[Zidovudine]]: may increase zidovudine serum concentration and lead to toxicity.

===Overdose and toxicity===
{| class=&quot;wikitable&quot; align=&quot;right&quot;
|+ Therapeutic range of valproic acid
|-
|'''Form'''
|'''Lower limit''' 
|'''Upper limit'''
|'''Unit'''
|- 
| rowspan=2| Total (including&lt;br&gt; [[Plasma protein binding|protein bound]])
| 50&lt;ref name=mass&gt;{{cite web|url=http://emedicine.medscape.com/article/2090462-overview|title=Valproic Acid Level|first=Suzanne|last=Bentley|date=Dec 11, 2013|accessdate=2015-06-05|publisher=[[Medscape]]}}&lt;/ref&gt; || 125&lt;ref name=mass/&gt; || µg/mL or mg/l
|-
| 350&lt;ref name=molar&gt;{{cite web|url=https://www.cadth.ca/media/pdf/lab-tests/06_Free_Valproic_Acid_Assay_e.pdf|title=Free Valproic Acid Assay (Reference — 2013.03.006) Notice of Assessment|date=April 2014|publisher=Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS’s permission|accessdate=2015-06-05}}&lt;/ref&gt; || 700&lt;ref name=molar/&gt; || μmol/L
|-
| rowspan=2| Free
| 6&lt;ref name=mass/&gt; || 22&lt;ref name=mass/&gt; || µg/mL or mg/l
|-
| 35&lt;ref name=molar/&gt; || 70&lt;ref name=molar/&gt; || μmol/L
|}

Excessive amounts of valproic acid can result in sleepiness, tremor, stupor, respiratory depression, coma, [[metabolic acidosis]], and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100&amp;nbsp;mg/l during controlled therapy, but may reach 150–1500&amp;nbsp;mg/l following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ [[Chromatography|gas or liquid chromatography.]]&lt;ref&gt;{{cite journal | vauthors = Sztajnkrycer MD | title = Valproic acid toxicity: overview and management | journal = J. Toxicol. Clin. Toxicol. | volume = 40 | issue = 6 | pages = 789–801 | year = 2002 | pmid = 12475192 | doi = 10.1081/CLT-120014645 }}&lt;/ref&gt;
In contrast to other [[antiepileptic drugs]], at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (p''K''a of 4.9).&lt;ref&gt;{{cite journal | vauthors = Patsalos PN, Berry DJ | title = Therapeutic drug monitoring of antiepileptic drugs by use of saliva | journal = Ther Drug Monit | volume = 35 | issue = 1 | pages = 4–29 | year = 2013 | pmid = 23288091 | doi = 10.1097/FTD.0b013e31827c11e7 }}&lt;/ref&gt;

In severe intoxication, [[hemoperfusion]] or [[hemofiltration]] can be an effective means of hastening elimination of the drug from the body.&lt;ref&gt;{{cite journal | vauthors = Thanacoody RH | title = Extracorporeal elimination in acute valproic acid poisoning | journal = Clin Toxicol (Phila) | volume = 47 | issue = 7 | pages = 609–616 | year = 2009 | pmid = 19656009 | pmc =  | doi = 10.1080/15563650903167772 }}&lt;/ref&gt;&lt;ref&gt;R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1622-1626.&lt;/ref&gt; Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored.&lt;ref name=&quot;:0&quot; /&gt; Supplemental [[Carnitine|&lt;small&gt;L&lt;/small&gt;-carnitine]] is indicated in patients having an acute overdose&lt;ref name=pmid16277730&gt;{{cite journal | vauthors = Lheureux PE, Penaloza A, Zahir S, Gris M | title = Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? | journal = Crit Care | volume = 9 | issue = 5 | pages = 431–440 | year = 2005 | pmid = 16277730 | pmc = 1297603 | doi = 10.1186/cc3742 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Mock CM, Schwetschenau KH | title = Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy | journal = Am J Health Syst Pharm | volume = 69 | issue = 1 | pages = 35–39 | year = 2012 | pmid = 22180549 | pmc =  | doi = 10.2146/ajhp110049 }}&lt;/ref&gt; and also [[Preventive medicine|prophylactically]]&lt;ref name=pmid16277730/&gt; in high risk patients. [[Acetylcarnitine|Acetyl-&lt;small&gt;L&lt;/small&gt;-carnitine]] lowers [[hyperammonemia]] less markedly&lt;ref&gt;{{cite journal | vauthors = Matsuoka M, Igisu H | title = Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia | journal = Biochem. Pharmacol. | volume = 46 | issue = 1 | pages = 159–164 | year = 1993 | pmid = 8347126 | doi = 10.1016/0006-2952(93)90360-9 }}&lt;/ref&gt; than [[Carnitine|&lt;small&gt;L&lt;/small&gt;-carnitine]].  &lt;!-- It is important for people to know the comparison between L-carnitine and Acetyl-L-carnitine for VPA induced hyperammonemia. --&gt;

==Mechanism of action==

Although the mechanism of action of valproate is not fully understood,&lt;ref name = TGA/&gt; it has recently been shown to protect against a seizure-induced reduction in [[phosphatidylinositol (3,4,5)-trisphosphate]] (PIP3) as a potential therapeutic mechanism.&lt;ref&gt;{{cite journal | vauthors = Chang P, Walker MC, Williams RS | title = Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid | journal = Neurobiol. Dis. | volume = 62 | pages = 296–306 | year = 2014 | pmid = 24148856 | pmc = 3898270 | doi = 10.1016/j.nbd.2013.10.017 }}&lt;/ref&gt; In addition, its anticonvulsant effect has been attributed to the blockade of voltage-dependent sodium channels and increased brain levels of [[Gamma-Aminobutyric acid|gamma-aminobutyric acid]] (GABA).&lt;ref name = TGA/&gt; The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate.&lt;ref name = TGA/&gt; In animals, sodium valproate raises cerebral and cerebellar levels of the inhibitory synaptic neurotransmitter, GABA, possibly by inhibiting GABA degradative enzymes, such as [[GABA transaminase]], [[succinate-semialdehyde dehydrogenase]] and by inhibiting the re-uptake of GABA by neuronal cells.&lt;ref name = TGA/&gt;

It also has [[Histone deacetylase inhibitor|histone deacetylase-inhibiting effects]]. The inhibition of histone deacetylase, by promoting more transcriptionally active chromatin structures, likely presents the epigenetic mechanism for regulation of many of the neuroprotective effects attributed to valproic acid. Intermediate molecules mediating these effects include [[VEGF]], [[BDNF]], and [[GDNF]].&lt;ref&gt;{{cite journal | vauthors = Kostrouchová M, Kostrouch Z, Kostrouchová M | title = Valproic acid, a molecular lead to multiple regulatory pathways | journal = Folia Biol. (Praha) | volume = 53 | issue = 2 | pages = 37–49 | year = 2007 | pmid = 17448293 | url = http://fb.cuni.cz/Data/files/folia_biologica/volume_53_2007_2/FB2007A0007.pdf | format = PDF }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Chiu CT, Wang Z, Hunsberger JG, Chuang DM | title = Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder | journal = Pharmacol. Rev. | volume = 65 | issue = 1 | pages = 105–142 | year = 2013 | pmid = 23300133 | pmc = 3565922 | doi = 10.1124/pr.111.005512 | url = http://pharmrev.aspetjournals.org/content/65/1/105.long }}&lt;/ref&gt;

Valproic acid has been found to be an [[receptor antagonist|antagonist]] of the [[androgen receptor|androgen]] and [[progesterone receptor]]s, and hence as a [[non-steroidal]] [[antiandrogen]] and [[antiprogestogen]], at concentrations much lower than therapeutic serum levels.&lt;ref name=&quot;pmid16165177&quot;&gt;{{cite journal | vauthors = Death AK, McGrath KC, Handelsman DJ | title = Valproate is an anti-androgen and anti-progestin | journal = Steroids | volume = 70 | issue = 14 | pages = 946–53 | year = 2005 | pmid = 16165177 | doi = 10.1016/j.steroids.2005.07.003 | url = }}&lt;/ref&gt; In addition, the drug has been identified as a potent [[aromatase inhibitor]], and suppresses [[estrogen]] concentrations.&lt;ref name=&quot;WyllieCascino2012&quot;&gt;{{cite book|vauthors = Wyllie E, Cascino GD, Gidal BE, Goodkin HP|title=Wyllie's Treatment of Epilepsy: Principles and Practice|url=http://books.google.com/books?id=j9t6Qg0kkuUC&amp;pg=PA288-IA37|date=17 February 2012|publisher=Lippincott Williams &amp; Wilkins|isbn=978-1-4511-5348-4|pages=288–}}&lt;/ref&gt; These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment.&lt;ref name=&quot;pmid16165177&quot; /&gt;&lt;ref name=&quot;WyllieCascino2012&quot; /&gt;

==History==
Valproic acid was first synthesized in 1882 by [[Beverly S. Burton]] as an [[analog (chemistry)|analogue]] of [[valeric acid]], found naturally in [[Valerian (herb)|valerian]].&lt;ref&gt;{{cite journal | vauthors = Burton BS | year = 1882 | title = On the propyl derivatives and decomposition products of ethylacetoacetate | url = | journal = Am Chem J. | volume = 3 | issue = | pages = 385–395 }}&lt;/ref&gt; Valproic acid is a [[carboxylic acid]], a clear liquid at room temperature. For many decades, its only use was in laboratories as a &quot;metabolically inert&quot; solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented [[pentylenetetrazol]]-induced convulsions in [[laboratory rats]].&lt;ref&gt;{{cite journal | vauthors = Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M | title = [Pharmacodynamic properties of N-dipropylacetic acid] | language = French | journal = Therapie | volume = 18 | pages = 435–438 | year = 1963 | pmid = 13935231 | trans_title = Pharmacodynamic properties of N-dipropylacetic acid }}&lt;/ref&gt; It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide.&lt;ref&gt;{{cite journal | vauthors = Perucca E | title = Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience | journal = CNS Drugs | volume = 16 | issue = 10 | pages = 695–714 | year = 2002 | pmid = 12269862 | doi = 10.2165/00023210-200216100-00004 }}&lt;/ref&gt; Valproic acid has also been used for migraine [[Preventive healthcare|prophylaxis]] and bipolar disorder.&lt;ref&gt;{{cite journal | vauthors = Henry TR | title = The history of valproate in clinical neuroscience | journal = Psychopharmacol Bull | volume = 37 Suppl 2 | pages = 5–16 | year = 2003 | pmid = 14624229 }}&lt;/ref&gt;

==Approval status==
{| class = wikitable
|-
! Indications
! {{flagicon|USA}}&lt;br/&gt;[[Food and Drug Administration|FDA]]-labelled indication?&lt;ref name = MSR/&gt; 
! {{flagicon|AUS}}&lt;br/&gt;[[Therapeutic Goods Administration|TGA]]-labelled indication?&lt;ref name = AMH&gt;{{cite book | title = Australian Medicines Handbook | year = 2013 | publisher = The Australian Medicines Handbook Unit Trust | isbn = 978-0-9805790-9-3 | edition = 2013 | place = Adelaide | editor = Rossi, S }}&lt;/ref&gt;
! scope=&quot;col&quot; |{{flagicon|GBR}}&lt;br/&gt;[[Medicines and Healthcare Products Regulatory Agency|MHRA]]-labelled indication?&lt;ref name = BNF&gt;{{cite book | last1 = Joint Formulary Committee| title = British National Formulary (BNF)  | isbn = 978-0-85711-084-8 | edition = 65 | location = London, UK | publisher = Pharmaceutical Press}}&lt;/ref&gt;
! Literature support
|-
| Epilepsy || {{yes}} || {{yes}} || {{yes}} || Limited (depends on the seizure type; it can help with certain kinds of seizures: drug-resistant epilepsy, partial and absence seizures, can be used against [[glioblastoma]] and other tumors both to improve survival and treat seizures, and against tonic-clonic seizures and status epilepticus).&lt;ref&gt;{{cite journal | vauthors = Rimmer EM, Richens A | title = An update on sodium valproate | journal = Pharmacotherapy | volume = 5 | issue = 3 | pages = 171–84 | date = May–June 1985 | pmid = 3927267 | doi = 10.1002/j.1875-9114.1985.tb03413.x }}&lt;/ref&gt;&lt;ref&gt;http://www.nejm.org/doi/full/10.1056/NEJMoa0902014&lt;/ref&gt;&lt;ref&gt;http://www.neurology.org/content/84/14_Supplement/P1.238.short&lt;/ref&gt;&lt;ref&gt;http://neuro-oncology.oxfordjournals.org/content/16/suppl_2/ii21.3.short&lt;/ref&gt;
|-
| Bipolar mania || {{yes}} || {{yes}} || {{yes}} || Limited.&lt;ref&gt;{{cite journal | vauthors = Vasudev K, Mead A, Macritchie K, Young AH | title = Valproate in acute mania: is our practice evidence based? | journal = Int J Health Care Qual Assur | volume = 25 | issue = 1 | pages = 41–52 | year = 2012 | pmid = 22455007 | doi = 10.1108/09526861211192395 }}&lt;/ref&gt;
|-
| Bipolar depression || {{no}} || {{no}} || {{no}} || Moderate.&lt;ref&gt;{{cite journal | vauthors = Bond DJ, Lam RW, Yatham LN | title = Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis | journal = J Affect Disord | volume = 124 | issue = 3 | pages = 228–334 | year = 2010 | pmid = 20044142 | doi = 10.1016/j.jad.2009.11.008 }}&lt;/ref&gt;
|-
| Bipolar maintenance || {{no}} || {{no}} || {{no}} || Limited.&lt;ref&gt;{{cite journal | vauthors = Haddad PM, Das A, Ashfaq M, Wieck A | title = A review of valproate in psychiatric practice | journal = Expert Opin Drug Metab Toxicol | volume = 5 | issue = 5 | pages = 539–51 | year = 2009 | pmid = 19409030 | doi = 10.1517/17425250902911455 }}&lt;/ref&gt;
|-
| Migraine prophylaxis || {{yes}} || {{Yes}} (accepted) || {{no}} || Limited.
|-
| Acute migraine management || {{no}} || {{no}} || {{no}} || Only negative results.&lt;ref&gt;{{cite journal | vauthors = Frazee LA, Foraker KC | title = Use of intravenous valproic acid for acute migraine | journal = Ann Pharmacother | volume = 42 | issue = 3 | pages = 403–7 | year = 2008 | pmid = 18303140 | doi = 10.1345/aph.1K531 }}&lt;/ref&gt;
|-
| Schizophrenia || {{no}} || {{no}} || {{no}} || Weak and mostly negative evidence.&lt;ref&gt;{{cite journal | vauthors = Schwarz C, Volz A, Li C, Leucht S | title = Valproate for schizophrenia | journal = Cochrane Database Syst Rev | issue = 3 | pages = CD004028 | year = 2008 | pmid = 18646098 | doi = 10.1002/14651858.CD004028.pub3 | url = http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004028.pub3/pdf | format = PDF }}&lt;/ref&gt;
|-
| Agitation in dementia || {{no}} || {{no}} || {{no}} || Weak and mostly negative evidence.&lt;ref&gt;{{cite journal | vauthors = Lonergan E, Luxenberg J | title = Valproate preparations for agitation in dementia | journal = Cochrane Database Syst Rev | issue = 3 | pages = CD003945 | year = 2009 | pmid = 19588348 | doi = 10.1002/14651858.CD003945.pub3 | url = http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003945.pub3/pdf | format = PDF }}&lt;/ref&gt;
|-
| [[Fragile X syndrome]] || {{yes}} (orphan) || {{no}} || {{no}} || Limited.&lt;ref&gt;{{cite journal | vauthors = Chiu CT, Wang Z, Hunsberger JG, Chuang DM | title = Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder | journal = Pharmacol. Rev. | volume = 65 | issue = 1 | pages = 105–142 | year = 2013 | pmid = 23300133 | pmc = 3565922 | doi = 10.1124/pr.111.005512 | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565922/pdf/pr.111.005512.pdf | format = PDF }}&lt;/ref&gt;
|-
| [[Familial adenomatous polyposis]] || {{yes}} (orphan) || {{no}} || {{no}} || Limited. 
|-
| Chronic pain &amp; fibromyalgia || {{no}} || {{no}} || {{no}} || Limited.&lt;ref&gt;{{cite journal | vauthors = Gill D, Derry S, Wiffen PJ, Moore RA | title = Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults | journal = Cochrane Database Syst Rev | issue = 10 | pages = CD009183 | year = 2011 | pmid = 21975791 | doi = 10.1002/14651858.CD009183.pub2 | url = http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009183.pub2/pdf | format = PDF }}&lt;/ref&gt;
|-
| Alcohol hallucinosis || {{no}} || {{no}} || {{no}} || One randomised double-blind placebo-controlled trial.&lt;ref&gt;{{cite journal | vauthors = Aliyev ZN, Aliyev NA | title = Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study | journal = Alcohol Alcohol. | volume = 43 | issue = 4 | pages = 456–459 | date = July–August 2008 | pmid = 18495806 | doi = 10.1093/alcalc/agn043 | url = http://alcalc.oxfordjournals.org/content/43/4/456.full.pdf | format = PDF }}&lt;/ref&gt;
|-
| Intractable hiccups || {{no}} || {{no}} || {{no}} || Limited, five case reports support its efficacy, however.&lt;ref&gt;{{cite journal | vauthors = Jacobson PL, Messenheimer JA, Farmer TW | title = Treatment of intractable hiccups with valproic acid | journal = Neurology | volume = 31 | issue = 11 | pages = 1458–1458 | year = 1981 | pmid = 6796902 | doi = 10.1212/WNL.31.11.1458 }}&lt;/ref&gt;
|-
| Non-epileptic myoclonus || {{no}} || {{no}} || {{no}} || Limited, three case reports support its efficacy, however.&lt;ref&gt;{{cite journal | vauthors = Sotaniemi K | title = Valproic acid in the treatment of nonepileptic myoclonus | journal = Arch. Neurol. | volume = 39 | issue = 7 | pages = 448–9 | year = 1982 | pmid = 6808975 | doi = 10.1001/archneur.1982.00510190066025 }}&lt;/ref&gt;
|-
| Cluster headaches || {{no}} || {{no}} || {{no}} || Limited, two case reports support its efficacy.&lt;ref&gt;{{cite journal | vauthors = Wheeler SD | title = Significance of migrainous features in cluster headache: divalproex responsiveness | journal = Headache | volume = 38 | issue = 7 | pages = 547–51 | date = July–August 1998 | pmid = 15613172 | doi = 10.1046/j.1526-4610.1998.3807547.x }}&lt;/ref&gt;
|-
| [[West syndrome]] || {{no}} || {{no}} || {{no}} || A prospective clinical trial supported its efficacy in treating infantile spasms.&lt;ref&gt;{{cite journal | vauthors = Siemes H, Spohr HL, Michael T, Nau H | title = Therapy of infantile spasms with valproate: results of a prospective study | journal = Epilepsia | volume = 29 | issue = 5 | pages = 553–60 | date = September–October 1988 | pmid = 2842127 | doi = 10.1111/j.1528-1157.1988.tb03760.x }}&lt;/ref&gt;
|-
| HIV infection eradication || {{no}} || {{no}} || {{no}} || Double-blind placebo-controlled trials have been negative.&lt;ref&gt;{{cite journal | vauthors = Smith SM | title = Valproic acid and HIV-1 latency: beyond the sound bite | journal = Retrovirology | volume = 2 | issue = 1 | pages = 56 | year = 2005 | pmid = 16168066 | pmc = 1242254 | doi = 10.1186/1742-4690-2-56 | url = http://www.retrovirology.com/content/pdf/1742-4690-2-56.pdf | format = PDF }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR | title = Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study | journal = HIV Med. | volume = 13 | issue = 5 | pages = 291–6 | year = 2012 | pmid = 22276680 | doi = 10.1111/j.1468-1293.2011.00975.x }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM | title = Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection | journal = PLoS ONE | volume = 5 | issue = 2 | pages = e9390 | year = 2010 | pmid = 20186346 | pmc = 2826423 | doi = 10.1371/journal.pone.0009390 | url = http://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0009390&amp;representation=PDF | format = PDF }}&lt;/ref&gt;
|-
| [[Myelodysplastic syndrome]] || {{no}} || {{no}} || {{no}} || Several clinical trials have confirmed its efficacy as a monotherapy,&lt;ref name = m2001&gt;{{cite journal | vauthors = Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A'Hern R | title = A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain | journal = J Pain Symptom Manage | volume = 21 | issue = 3 | pages = 204–9 | year = 2001 | pmid = 11239739 | doi = 10.1016/S0885-3924(00)00266-9 | url = http://bloodjournal.hematologylibrary.org/content/104/5/1266.full.pdf | format = PDF }}&lt;/ref&gt; as an adjunct to [[tretinoin]]&lt;ref name = m2001/&gt; and as an adjunct to hydralazine.&lt;ref&gt;{{cite journal | vauthors = Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A | title = Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial | journal = Ann. Hematol. | volume = 90 | issue = 4 | pages = 379–387 | year = 2011 | pmid = 20922525 | doi = 10.1007/s00277-010-1090-2 }}&lt;/ref&gt;
|-
| [[Acute myeloid leukaemia]] || {{no}} || {{no}} || {{no}} || Two clinical trials have confirmed its efficacy in this indication as both a monotherapy and as an adjunct to [[tretinoin]].&lt;ref&gt;{{cite journal | vauthors = Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG | title = Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia | journal = Cancer | volume = 104 | issue = 12 | pages = 2717–2725 | year = 2005 | pmid = 16294345 | doi = 10.1002/cncr.21589 | url = http://onlinelibrary.wiley.com/doi/10.1002/cncr.21589/pdf | format = PDF }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N | title = The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia | journal = Cancer | volume = 106 | issue = 1 | pages = 112–119 | year = 2006 | pmid = 16323176 | doi = 10.1002/cncr.21552 | url = http://onlinelibrary.wiley.com/doi/10.1002/cncr.21552/pdf | format = PDF }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Fredly H, Gjertsen BT, Bruserud O | title = Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents | journal = Clin Epigenetics | volume = 5 | issue = 1 | pages = 12 | year = 2013 | pmid = 23898968 | pmc = 3733883 | doi = 10.1186/1868-7083-5-12 | url = http://www.clinicalepigeneticsjournal.com/content/pdf/1868-7083-5-12.pdf | format = PDF }}&lt;/ref&gt;
|-
| [[Cervical cancer]] || {{no}} || {{no}} || {{no}} || One clinical trial supports its use here.&lt;ref&gt;{{cite journal | vauthors = Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S, Dueñas-González A | title = A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results | journal = Med. Oncol. | volume = 28 Suppl 1 | pages = S540–6 | year = 2011 | pmid = 20931299 | doi = 10.1007/s12032-010-9700-3 }}&lt;/ref&gt;
|-
| [[Malignant melanoma]] || {{no}} || {{no}} || {{no}} || One phase II study has seemed to discount its efficacy.&lt;ref&gt;{{cite journal | vauthors = Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A | title = A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma | journal = Br. J. Cancer | volume = 100 | issue = 1 | pages = 28–36 | year = 2009 | pmid = 19127265 | pmc = 2634690 | doi = 10.1038/sj.bjc.6604817 | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634690/pdf/6604817a.pdf | format = PDF }}&lt;/ref&gt;
|-
| [[Breast cancer]] || {{no}} || {{no}} || {{no}} || A phase II study has supported its efficacy.&lt;ref&gt;{{cite journal | vauthors = Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D | title = Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC | journal = Clin. Cancer Res. | volume = 15 | issue = 7 | pages = 2488–96 | year = 2009 | pmid = 19318486 | doi = 10.1158/1078-0432.CCR-08-1930 | url = http://clincancerres.aacrjournals.org/content/15/7/2488.full.pdf | format = PDF }}&lt;/ref&gt;
|-
| [[Impulse control disorder]] || {{no}} || {{no}} || {{no}} || Limited.&lt;ref name=Hicks&gt;{{cite journal | vauthors = Hicks CW, Pandya MM, Itin I, Fernandez HH | title = Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease | journal = Parkinsonism Relat. Disord. | volume = 17 | issue = 5 | pages = 379–81 | year = 2011 | pmid = 21459656 | doi = 10.1016/j.parkreldis.2011.03.003 | url = http://www.ncbi.nlm.nih.gov/pubmed/21459656 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, McFarland NR, Okun MS | title = Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease | journal = J. Neurol. | volume = 260 | issue = 2 | pages = 521–7 | year = 2013 | pmid = 23007193 | doi = 10.1007/s00415-012-6669-1 | url = http://www.ncbi.nlm.nih.gov/pubmed/23007193 }}&lt;/ref&gt;
|}

==Formulations==
{{Drugbox
| drug_name = Sodium valproate
| verifiedrevid = 464404696
| IUPAC_name = sodium 2-propylpentanoate
| image = Sodium-valproate-2D-skeletal.png
| image2 = Valproato Sódico.png
| width = 180
&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1069-66-5
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 13428
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5VOM6GYJ0D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00710
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9925
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 433
&lt;!--Chemical data--&gt;
| C=8 | H=15 | Na=1 | O=2
| smiles = [Na+].[O-]C(=O)C(CCC)CCC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AEQFSUDEHCCHBT-UHFFFAOYSA-M
}}
Valproate exists in two main molecular variants: ''sodium valproate'' and ''valproic acid without sodium'' (often implied by simply ''valproate''). A mixture between these two is termed ''semisodium valproate''. It is unclear whether there is any difference in efficacy between these variants, except from the fact that about 10% more of ''sodium vaproate'' is needed than ''valproic acid without sodium'' to compensate for the sodium itself.&lt;ref&gt;{{cite book|title=The Maudsley Prescribing Guidelines, Tenth Edition|author1=David Taylor |author2=Carol Paton |author3=Shitij Kapur |edition=10, revised|publisher=CRC Press|year=2009|isbn=9780203092835|url=https://books.google.se/books?id=pbvLBQAAQBAJ&amp;pg=PA124|page=124}}&lt;/ref&gt;

===Brand names of valproic acid===
&lt;!-- Please do not add sodium valproate-based products to this list. That drug has its own list below --&gt;
Branded products include:
{{colbegin|2}}
* Absenor ([[Orion Corporation]] Finland)
* Convulex ([[G.L. Pharma GmbH]] Austria)
* Depakene ([[Abbott Laboratories]] in US and Canada)
* Depakine ([[Sanofi Aventis]] France)
* Depakine ([[Sanofi Synthelabo]] Romania)
* Depalept ([[Sanofi Aventis]] Israel)
* Deprakine ([[Sanofi Aventis]] Finland)
* Encorate ([[Sun Pharmaceuticals]] India)
* Epival ([[Abbott Laboratories]] US and Canada)
* Epilim ([[Sanofi Synthelabo]] Australia and South Africa)
* Stavzor ([[Noven Pharmaceuticals|Noven Pharmaceuticals Inc.]])
* Valcote ([[Abbott Laboratories]] Argentina)
* Valpakine ([[Sanofi Aventis]] Brazil)
{{colend}}

===Brand names of sodium valproate===

====Portugal====
* Tablets &amp;ndash; Diplexil-R by [[Bial]].

====United States====
* Intravenous injection &amp;ndash; Depacon by [[Abbott Laboratories]].
* Syrup &amp;ndash; Depakene by [[Abbott Laboratories]]. (Note Depakene ''capsules'' are valproic acid).
* [[Depakote]] tablets are a mixture of sodium valproate and valproic acid.
* Tablets &amp;ndash; Eliaxim by [[Bial]].

====Australia====
*Epilim Crushable Tablets [[Sanofi]]
*Epilim Sugar Free Liquid    [[Sanofi]]
*Epilim Syrup    [[Sanofi]]
*Epilim Tablets    [[Sanofi]]
*Sodium Valproate Sandoz Tablets    [[Sanofi]]
*Valpro Tablets    [[Alphapharm]]
*Valproate Winthrop Tablets    [[Sanofi]]
*Valprease tablets Sigma

====New Zealand====
*Epilim by [[Sanofi-Aventis]]

All the above formulations are [[Pharmaceutical Management Agency|Pharmac]]-subsidised.&lt;ref&gt;{{cite web |url= http://www.pharmac.govt.nz/Schedule?osq=Sodium%20valproate |title= Sodium valproate -- Pharmaceutical Schedule |publisher= Pharmaceutical Management Agency |accessdate= 22 June 2014}}&lt;/ref&gt;

====UK====
* Depakote Tablets (as in USA)
* Tablets &amp;ndash; Orlept by Wockhardt and Epilim by [[Sanofi]]
* Oral solution &amp;ndash; Orlept Sugar Free by Wockhardt and Epilim by Sanofi
* Syrup &amp;ndash; Epilim by Sanofi-Aventis
* Intravenous injection &amp;ndash; Epilim Intravenous by Sanofi
* Extended release tablets &amp;ndash; Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
* Enteric-coated tablets &amp;ndash; Epilim EC200 by Sanofi is a 200-mg sodium valproate [[Enteric coating|enteric-coated]] tablet.

=====UK only=====
* Capsules &amp;ndash; Episenta prolonged release by Beacon
* Sachets &amp;ndash; Episenta prolonged release by Beacon
* Intravenous solution for injection &amp;ndash; Episenta solution for injection by Beacon

====Germany, Switzerland, Norway, Finland, Sweden====
* Tablets &amp;ndash; Orfiril by Desitin Pharmaceuticals
* Intravenous injection &amp;ndash; Orfiril IV by Desitin Pharmaceuticals

====South Africa====
* Syrup &amp;ndash; Convulex by Byk Madaus
* Tablets &amp;ndash; Epilim by Sanofi-synthelabo

====Malaysia====
* Tablets &amp;ndash; Epilim by Sanofi-Aventis

====Romania====
* Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
* Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets

====Canada====
* Intravenous injection &amp;ndash; Epival or Epiject by [[Abbott Laboratories]].
* Syrup &amp;ndash; Depakene by [[Abbott Laboratories]] its generic formulations include [http://www.apotex.ca/Products/EN/Detail.asp?MaterialNumber=000000000000042290 Apo-Valproic] and [http://www.ratiopharm.ca/e/Products/productSearch.asp?Cap=V ratio-Valproic].

====Japan====
* Tablets &amp;ndash; Depakene by [[Kyowa Hakko Kirin]]
* Extended release tablets &amp;ndash; Depakene-R by Kyowa Hakko Kogyo and Selenica-R by [[Kowa]]
* Syrup &amp;ndash; Depakene by Kyowa Hakko Kogyo

====Europe====
In much of Europe, Depakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.

====Taiwan====
*Tablets (white round tablet) – Depakine ({{zh-cp|c=帝拔癲|p=di-ba-dian}}) by [[Sanofi-Aventis|Sanofi Winthrop Industrie]] (France)

====Israel====
Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above.  Manufactured and distributed by [[Sanofi-Aventis]].

==== India, Russia and [[Commonwealth of Independent States|CIS]] countries ====
* Valprol CR by Intas Pharmaceutical (India) 
* Encorate Chrono by Sun Pharmaceutical (India)
* Serven Chrono by Leeven APL Biotech (India)

===Brand names of valproate semisodium===
* Brazil &amp;ndash; Depakote by [[Abbott Laboratories]]
* Canada &amp;ndash; Epival by Abbott Laboratories
* Mexico &amp;ndash; Epival and Epival ER (extended release) by Abbott Laboratories
* United Kingdom &amp;ndash; Depakote (for psychiatric conditions) and Epilim (for epilepsy) by [[Sanofi-Aventis]] and generics
* United States &amp;ndash; Depakote and Depakote ER (extended release) by Abbott Laboratories and generics
* India &amp;ndash; Valance and Valance OD by Abbott Healthcare Pvt Ltd,Divalid ER by Linux laboratories Pvt Ltd,Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
* Germany &amp;ndash; Ergenyl Chrono by Sanofi-Aventis and generics
* Chile &amp;ndash; Valcote and Valcote ER by Abbott Laboratories
* France and other European countries &amp;mdash; Depakote
* Peru &amp;ndash; Divalprax by AC Farma Laboratories
* China &amp;ndash; Diprate OD

==Research==
{{as of|2016}} it is also registered for 45 phase II clinical trials (some completed) for various cancers.&lt;ref&gt;[https://clinicaltrials.gov/ct2/results?term=valproate+AND+cancer&amp;phase=1 Phase II cancer trials of valproic acid]&lt;/ref&gt;

== References ==
{{Reflist|colwidth=30em}}

== Further reading ==
&lt;!--Only freely available review articles are being added here. The PDF link, if any, can be added directly to the respective template. Items are sorted by recency. --&gt;
* {{cite journal | vauthors = Chateauvieux S, Morceau F, Dicato M, Diederich M | title = Molecular and therapeutic potential and toxicity of valproic acid | journal = J. Biomed. Biotechnol. | volume = 2010 | pages = 1 | year = 2010 | pmid = 20798865 | pmc = 2926634 | doi = 10.1155/2010/479364 | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926634/pdf/JBB2010-479364.pdf | format = PDF }}
* {{cite journal | vauthors = Monti B, Polazzi E, Contestabile A | title = Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection | journal = Curr Mol Pharmacol | volume = 2 | issue = 1 | pages = 95–109 | year = 2009 | pmid = 20021450 | doi = 10.2174/1874467210902010095 | url = http://www.benthamscience.com/cmp/samples/cmp2-1/0011CMP.pdf | format = PDF }}

== External links ==
* [http://www.psycheducation.org/depression/meds/valproate.htm PsychEducation: Valproate/divalproex (divalproex)]
* [http://ctdbase.org/detail.go?type=chem&amp;acc=D014635 The Comparative Toxicogenomics Database:Valproic Acid]
* [http://www.chemicalland21.com/lifescience/phar/VALPROIC%20ACID.htm Chemical Land21: Valproic Acid]
* [http://www.rxlist.com/cgi/generic2/depakene.htm RXList.com: Depakene (Valproic Acid)] (U.S.)
* [http://home.intekom.com/pharm/byk/convulex.html South African Electronic Package Inserts: Convulex]
* [http://www.medbroadcast.com/drug_info_list.asp?search_letter=VALPROIC%20ACID Med Broadcast.com: Valproic Acid] (Canadian)

{{Anticonvulsants}}
{{Mood stabilizers}}
{{GABAergics}}
{{HDAC inhibitors}}
{{Ion channel modulators}}
{{Androgenics}}
{{Progestogenics}}
{{Steroid hormone metabolism modulators}}

{{DEFAULTSORT:Valproic Acid}}
[[Category:Antiandrogens]]
[[Category:Anticonvulsants]]
[[Category:Antiprogestogens]]
[[Category:Aromatase inhibitors]]
[[Category:Carboxylic acids]]
[[Category:GABA analogues]]
[[Category:GABA transaminase inhibitors]]
[[Category:Histone deacetylase inhibitors]]
[[Category:Mood stabilizers]]
[[Category:Teratogens]]
[[Category:World Health Organization essential medicines]]</text>
      <sha1>mocy15027irn8b64q8yity2k0c26cb1</sha1>
    </revision>
  </page>
</mediawiki>
